BGI CEO Wang Jun On Big Data, Drug Development And Fundamental Innovation: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Named “one of the ten people who mattered” in 2012 by the journal Nature, the BGI-Shenzhen co-founder talks about how big data will change the course of R&D, from drug development to agriculture to a new carbon world.
You may also be interested in...
After announcing the intent to form a partnership a year ago, Merck & Co. announced Sept. 13, a collaboration with BGI (formerly the Beijing Genomics Institute) for discovery and development of biomarkers and genomic technologies
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.